NCT05550961 APOLLO 11, Consortium of Italian Centers Involved in Treatment of Patients With Lung Cancer Treated With Innovative Therapies: Real World Data and Translational Reaserch
| NCT ID | NCT05550961 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano |
| Condition | NSCLC |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,200 participants |
| Start Date | 2022-10-01 |
| Primary Completion | 2027-10-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,200 participants in total. It began in 2022-10-01 with a primary completion date of 2027-10-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
APOLLO 11 main aim is to build a strong Italian long-lasting lung cancer network (in around 48 Italian centres) on real world data and translational research by creating a decentralized long-term national database (settle locally in each centre) and a "virtual" multilevel biobank in each centre. Besides, APOLLO 11 will take advantage of the translational research joint effort with the credo "unity is strength".
Eligibility Criteria
Inclusion Criteria: 1. Provision of signed and dated written informed consent, when applicable, by the patient or legally acceptable representative prior to any mandatory study-specific procedures, sampling, and analyses; 2. Patients must be ≥18 years of age at the time of signing the informed consent; 3. Histologically or cytologically confirmed lung cancer (NSCLC or SCLC) at any stage (I-IV) candidate to receive or already treated with innovative therapies (ICIs, target therapies and next generation therapies). Exclusion Criteria: 1. Patients who are or will be taking other unapproved antineoplastic therapies concurrently are not eligible. 2. Patients who have not received an oncological systemic innovative therapy at any setting 3. Patients received only local treatments (e.g., only surgery, or only radiotherapy) 4. Patients who received only standard chemotherapy are excluded. 5. Patients who received treatment therapies before 2010 are excluded.
Contact & Investigator
Carlo Genova
PRINCIPAL INVESTIGATOR
IRCCS Ospedale Policlinico San Martino, Genova
Frequently Asked Questions
Who can join the NCT05550961 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying NSCLC. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05550961 currently recruiting?
Yes, NCT05550961 is actively recruiting participants. Contact the research team at arsela.prelaj@istitutotumori.mi.it for enrollment information.
Where is the NCT05550961 trial being conducted?
This trial is being conducted at Milan, Italy.
Who is sponsoring the NCT05550961 clinical trial?
NCT05550961 is sponsored by Fondazione IRCCS Istituto Nazionale dei Tumori, Milano. The principal investigator is Carlo Genova at IRCCS Ospedale Policlinico San Martino, Genova. The trial plans to enroll 1,200 participants.